Skip to main content

Injectable Drug Delivery Market to Hit USD 1,251.28 Billion with 12.9% CAGR; Rising Cases of COVID-19 Pandemic to Promote Growth, says Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Nov. 11, 2020 (GLOBE NEWSWIRE) — The global injectable drug delivery market size is anticipated to rise at a CAGR of 12.9% to reach USD 1,251.28 billion by the end of 2027 owing to the increasing prevalence of various diseases and the need for easy drug delivery to various target sites. Injectable drug delivery helps to provide effective drug delivery experience with speedy delivery. It is also considered as one of the most efficient routes of administration, thus ensuring improved patient experience. As per a report by Fortune Business Insights. The value of this market was USD 483.45 billion in the year 2019 and the forecast period is set between 2020 and 2027. North America accounted for the largest injectable drug delivery market share in 2019 with a revenue of USD 172.67 billion.Major Industry Developments of the Market for Injectable Drug Delivery include:November 2017 – A new drug delivery system called the SMARTDOSE was introduced by West Pharmaceutical Services Inc. for treating patients with heart issues. July 2019 – A new auto-injector drug for Humira was launched by Eisai Co. Ltd. and AbbVie to treat autoimmune diseases.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/injectable-drug-delivery-market-101044
Rising Awareness about Minimal Invasive Treatment Mode to Add ImpetusThe rising geriatric population and their vulnerability to various diseases stand as key factors boosting the global injectable drug delivery market growth. This, coupled with the rising prevalence of chronic diseases such as cancer, diabetes, heart disorders, and others will also add impetus to the market.Moreover, clinical studies and the adoption of innovative products for drug delivery are expected to boost the market growth. The current COVID-19 pandemic that has propelled the intensity of casualty cases in medical centers all over the world is also aiding in the expansion of the market.Fortune Business Insights is offering special analytical reports on different markets that are impacted by the COVID-19 pandemic. These reports will help investors study the complete evaluations of the market, and current situation, and accordingly chalk out plans to gain maximum revenue in the coming years.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/injectable-drug-delivery-market-101044
North America Covered Dominant Share Accountable to Increasing Construction ActivitiesNorth America accounted for the largest injectable drug delivery market share in 2019 with a revenue of USD 172.67 billion. This is accountable to the increasing adoption of innovative injectable medical products by patients suffering from chronic diseases such as cancer, diabetes, and other autoimmune disorders.On the other side, the market in Asia Pacific is likely to rise with the fastest CAGR during the forecast period on account of the increasing prevalence of chronic diseases requiring medical aid on a regular basis, increasing awareness about drug delivery systems, and the rising inclination towards ready-to-use injectable from the conventional injectable.
Quick Buy –  Injectable Drug Delivery Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101044
Companies Focusing on Novel Product Development for Better Revenue GenerationThe competitive nature of the market for injectable drug delivery is consolidated in nature with a handful of players covering significant shares. These include companies such as SHL Medical AG, BD, and Insulet Corporation.However, the entry of more players in the coming years will result in the fragmented nature of the market. The major objective of the players is to engage in research and development of novel advanced injectable drug delivery products such as wearable, bluetooth equipped devices, and others to maintain their position. On the other hand, they are looking forward to intensify the overall competition.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/injectable-drug-delivery-market-101044
List of Key Players in the Injectable Drug Delivery Market include:Gerresheimer AG (Germany, Europe)BD (New Jersey, U.S)Insulet Corporation (Massachusetts, U.S)Ypsomed AG (Switzerland, Europe)SHL Medical AG (Switzerland, Europe)Eli Lilly and Company (Indiana, U.S)West Pharmaceutical Services, Inc. (Pennsylvania, U.S)Elcam Medical (Israel, Middle East)Pfizer Inc. (New York, U.S)
Segmentations:By Device Type   •              Conventional Injectable•              Pre-filled Syringes•              Auto-injectors•              Pen-injectors•              WearableBy Product Type •              Freeze-dried Products•              Injectable Sterile ProductsBy End User         •              Hospitals•              Home Care Settings•              Clinics•              OthersBy Geography      •              North America (the USA, and Canada)•              Europe (UK, Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)•              Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)•              Latin America (Brazil, Mexico and the Rest of the Latin America)•              Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/injectable-drug-delivery-market-101044
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:Drug Delivery Market Share & Industry Analysis, By Route of Administration (Injectable, Nasal, Topical & Transdermal, Oral and Others), By Type (Conventional and Advanced), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2019-2026Nasal Drug Delivery Market Share and Industry Analysis, By Type (Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and Nebulizers), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography Forecast till 2026Diabetic Ulcer Treatment Market Share and Industry Analysis, By Ulcer Type (Foot Ulcer (Neuropathic Ulcer, Ischemic Ulcer, and Neuro-ischemic Ulcer), Mouth Ulcer, and Others), By Treatment Type (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2019-2026Connected Drug Delivery Devices Market Share & Industry Analysis, By Type (Injectable Devices and Inhalation Devices & Others) By Technology (Bluetooth, NFC, and Others) By End User (Homecare Settings and Hospitals) and Regional Forecast, 2019-2026Vision Care Market Share & Industry Analysis, By Product Type (Eyewear, Intraocular Lens, and Ocular Health), By Distribution Channel (Retail Store, Online Store, Hospital & Clinics), and Regional Forecast, 2019-2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/injectable-drug-delivery-market-9202

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.